Citizens Petition
- Sustaining Partners
May 2012-
The Search for an Ideal Analgesic
June 2011-
Pharmacotherapy for Prescription Opioid Addiction
March 2011-
Advancing Safe Opioid Prescribing through Prescriber Training and Behavior Change
June 2010-
Payer Issues Related to Prescription Opioid Monitoring and Abuse
March 2010-
The role of Dentists in Preventing Opioid Abuse
July 2009-
Risk Evaluation and Mitigation Strategy for Prescription Opioids
April 2009-
Prescription Monitoring Research Update
November 2008-
Co-ingestion of Alcohol with Prescription Opioids
June 2008-
The Role of Urine Drug Monitoring in Pain Management
March 2008-
Sources of Diverted Prescription Opioids
September 2007-
Understanding the Types of Opioid Abusers
March 2007-
Responding to Signals of Opioid Abuse
November 2006-
Development of Abuse Deterrent Formulations
September 2006-
Best Practices in Opioid Risk Management
October 2005-
Opioid Abuse Resistance
March 2005-
Opioid Risk Management

Tufts Health Care Institute Program on
Opioid Risk Management

The mission of the Tufts Health Care Institute Program on Opioid Risk Management is to address challenges in the development and utilization of opioid analgesics, by engaging a multidisciplinary group of stakeholders focused on optimizing the benefits of opioid for pain management, and minimizing their risks, including abuse and diversion.

Sustaining Partners

Endo Pharmaceuticals    

Endo Pharmaceuticals is a specialty pharmaceutical company with an established leadership in pain management. Endo researches, develops, produces and markets prescription pharmaceuticals used primarily to treat and manage pain, and is expanding its presence in complementary therapeutic areas. Endo is committed to advancing the care of patients with acute and chronic pain through focused research and development programs, innovative technology and delivery systems, and educational initiatives that advocate the responsible use of pain medications.

King Pharmaceuticals

King Pharmaceuticals® began operations in January 1994, after purchasing the company’s Bristol Tennessee facility and assuming contracts to manufacture prescription pharmaceutical products for such prominent companies as SmithKline Beecham Corporation, predecessor to GlaxoSmithKline, and Novartis.

For the next ten years, King principally focused on the manufacture, acquisition, and marketing of previously approved products. Under new leadership, the company shifted its strategy to position itself to become a leading developer and acquirer of novel branded pharmaceutical products in later stages of development, focusing on three main therapeutic areas, cardiovascular/metabolics, neuroscience and hospital/acute care.

King’s labor force has grown from an initial 145 to approximately 2700 employees involved in every discipline of a major pharmaceutical company, including sales and marketing, research and development, regulatory affairs, quality management, and manufacturing.

Purdue Pharma                     

Purdue Pharma L.P., a privately held pharmaceutical company founded by physicians, is focused on the needs of patients. Together with its independent associated companies, Purdue is dedicated to finding, developing, and bringing to market new medicines and related products that promote health and healing. The company has long been known for its pioneering research on persistent pain, a principal cause of human suffering. Purdue has also applied its expertise to other therapeutic areas such as respiratory diseases, oncology, and bacterial infections, and to a growing line of non-prescription products including laxatives, microbicides, and nutraceuticals. The company is dedicated to serving the evolving needs of healthcare providers, patients, and caregivers with innovative prescription and non-prescription medicines. A commitment to innovation and caring spans every aspect of the organization, from discovering and introducing new medicines to demonstrating their medical value.

Purdue has led the battle against inadequate treatment of pain by developing sustained-release medications to manage pain and provide meaningful benefits for patients. Its sales, marketing, and medical education professionals provide the healthcare community with comprehensive educational materials and programs relating to pain management.

In 1993, to raise awareness of the importance of pain management, Purdue established Partners Against Pain®. This alliance of patients, caregivers, and healthcare providers seeks to alleviate unnecessary suffering by advancing standards of pain care through education and advocacy. Purdue has also assumed a leading role in addressing the serious public health problem of prescription drug abuse. The company has implemented a comprehensive program designed to assist in detection of the illegal trafficking and abuse of prescription drugs without compromising patient access to proper pain control.

At its research facilities in Cranbury, New Jersey, Purdue scientists are discovering new weapons against pain and developing innovative formulations and delivery systems to improve patient compliance and safety while at the same time reduce the risk of unwarranted product tampering. Hundreds of millions of dollars have been committed to the development of new forms of analgesics designed to be resistant to tampering while still providing safe and effective pain control for patients.


Contributing Partners

Millennium Laboratories

Millennium Laboratories is the leading research-based, clinical diagnostic company dedicated to improving the lives of people with chronic pain and/or addiction. The company provides healthcare professionals with medication monitoring, drug detection and pharmacogenetic testing services to personalize treatment plans to improve clinical outcomes and patient safety. More information can be found at www.millenniumlabs.com

Millennium Research Institute

Therapeutic drug monitoring company Millennium Laboratories established the non-profit Millennium Research Institute to address the questions at the forefront of pain management treatment that, when answered, will lead to further scientific discovery, advancements in the field of pain management, and improved treatment outcomes for those suffering with pain and pain-related disorders.

The mission of the Millennium Research Institute is to advance pain management and treatment outcomes through research, education and advocacy.

Millennium Research Institute is defining prescription drug compliance and diversion though development and dissemination of pharmacokinetic research to enhance pain management treatment and outcomes. The Institute’s research is increasing the understanding of drug metabolism to ensure safe utilization of pain management drugs and to provide evidence-based practice tools and information that supports pain professionals’ prescribing practices.

Millennium Research Institute maintains several national academic partnerships and supports collaborative research by accessing Millennium Laboratories’ unique database representing the U.S. pain population. Through its research and education programs, Millennium sits squarely in the community of professionals advancing the understanding of pain.

Additional Funders

Funding for the THCI Program on Opioid Risk Management summit meeting "Payer Issues Related to Prescription Opioid Monitoring and Abuse" in June 2010 was made possible (in part) by (PA-08-149) from the National Institute on Drug Abuse. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

© 2008 Tufts Health Care Institute •   Boston, MA 02111 •   (617) 636-1000